Image_5_Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.jpeg
B cell abnormalities are common in systemic lupus erythematosus (SLE), and include expansion of double negative (DN) and age-associated-like B cells (ABC-like). We aimed to investigate rituximab (RTX) effects on DN and ABC-like B-cell subsets and, when possible, also secondary effects on T cells. Fifteen SLE patients, fulfilling the ACR 1982 criteria, starting RTX and followed longitudinally up to two years, were analyzed for B- and T- lymphocyte subsets using multicolor flow cytometry. DN were defined as IgD-CD27- and ABC-like as CD11c+CD21- within the DN gate. Additional phenotyping was performed adding CXCR5 in the B-cell panel. Cellular changes were further analyzed in the context of the generation of anti-drug antibodies (ADA) against RTX and clinical information. The SLE patients were mainly females (86.6%), of median age 36.7 (29.8-49.4) years and disease duration of 6.1 (1.6-11.8) years. Within the DN subset, ABC-like (IgD-CD27-CD11c+CD21-) B cell frequency reduced from baseline median level of 20.4% to 11.3% (p=0.03), at early follow-up. The DN B cells were further subdivided based on CXCR5 expression. Significant shifts were observed at the early follow-up in the DN2 sub-cluster (CD11c+CXCR5-), which reduced significantly (-15.4 percentage points, p=0.02) and in the recently described DN3 (CD11c-CXCR5-) which increased (+13 percentage points, p=0.03). SLE patients treated with RTX are at high risk of developing ADA. In our cohort, the presence of ADA at 6 months was associated with lower frequencies of DN cells and to a more pronounced expansion of plasmablasts at early follow-up. The frequency of follicular helper T cells (TFH, CD4+PD-1+CXCR5+) and of peripheral helper T cells (TPH, CD4+PD-1+CXCR5-) did not change after RTX. A sub-cluster of PD-1highCD4+ T cells showed a significant decrease at later follow-up compared to early follow-up (p=0.0039). It is well appreciated that RTX transiently influences B cells. Here, we extend these observations to cell phenotypes which are believed to directly contribute to autoimmunity in SLE. We show early transient effects of RTX on ABC-like memory B cells, later effects on PD-1high CD4+ cells, and possible implications for RTX immunogenicity. Further insight in such effects and their monitoring may be of clinical relevance.
History
References
- https://doi.org//10.1038/nrrheum.2016.186
- https://doi.org//10.1111/j.1365-2249.2010.04309.x
- https://doi.org//10.4049/jimmunol.165.10.5970
- https://doi.org//10.1002/art.10949
- https://doi.org//10.1002/art.20592
- https://doi.org//10.4049/jimmunol.178.10.6624
- https://doi.org//10.1136/rmdopen-2020-001258
- https://doi.org//10.1016/j.immuni.2018.08.015
- https://doi.org//10.1182/blood-2011-01-331462
- https://doi.org//10.1182/blood-2011-01-330530
- https://doi.org//10.1146/annurev-immunol-092419-031130
- https://doi.org//10.1038/s41590-018-0056-8
- https://doi.org//10.1038/s41467-018-03750-7
- https://doi.org//10.4049/jimmunol.1601106
- https://doi.org//10.1038/s41590-019-0398-x
- https://doi.org//10.1016/j.immuni.2014.10.004
- https://doi.org//10.1093/rheumatology/kew297
- https://doi.org//10.1002/art.25032
- https://doi.org//10.1111/imr.12741
- https://doi.org//10.1038/nature20810
- https://doi.org//10.1172/jci.insight.130062
- https://doi.org//10.1136/annrheumdis-2020-216924
- https://doi.org//10.1186/ar3908
- https://doi.org//10.1002/art.1780251101
- https://doi.org//10.1002/art.22505
- https://doi.org//10.26226/morressier.59a3eda8d462b8028d895367
- https://doi.org//10.1186/s13075-021-02589-6
- https://doi.org//10.1038/44385
- https://doi.org//10.1111/j.1600-065X.2009.00767.x
- https://doi.org//10.1093/rheumatology/kez077
- https://doi.org//10.1126/sciimmunol.abh0891
- https://doi.org//10.1038/s41590-020-00814-z
- https://doi.org//10.3389/fimmu.2020.611004
- https://doi.org//10.3389/fimmu.2021.602539
- https://doi.org//10.1371/journal.pone.0075319
- https://doi.org//10.1002/art.39020
- https://doi.org//10.1093/rheumatology/kez228
- https://doi.org//10.4049/jimmunol.1600089
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity